Update on the Roche Sequencing Unit strategy and new acquisitions

The Roche Sequencing Unit is working diligently to introduce potentially disruptive sequencing technologies and solutions to the market. An overview of Roche’s emerging sequencing portfolio in the life sciences and healthcare will be presented including an update on Roche Sequencing Unit strategy and new acquisitions.

Additionally, Roche NimbleGen’s unique target enrichment technology will also be presented. The SeqCap EZ Exome and Custom System is the platform of choice by many universities, research institutes, medical centers and global genome centers; with a track record of hundreds of thousands of successfully sequenced samples each year. The SeqCap Epi System for targeted methyl-Seq brings unprecedented depth, flexibility and sample capacity to methylation assessment at single-base level on your genes of interest. The SeqCap RNA System can help you efficiently focus on specific transcripts and overcome challenges caused by low transcript abundance.  All these technologies enable the life science community to achieve their research goals more efficiently in order to understand the association that genomics and epigenomics have with diseases and biological processes.